申请人:Eli Lilly and Company
公开号:US20160176896A1
公开(公告)日:2016-06-23
The present invention provides thieno[2,3-c]pyrrol-4-one compounds that inhibit activity of extracellular-signal-regulated kinase (ERK) and may be useful in the treatment of cancer.
本发明提供了抑制细胞外信号调节激酶(ERK)活性的噻吩[2,3-c]吡咯-4-酮化合物,并可能在癌症治疗中有用。